dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Park, Julie |
dc.contributor.author | Villablanca, Judith |
dc.contributor.author | Hero, Barbara |
dc.contributor.author | Kushner, Brian H. |
dc.contributor.author | Wheatley, Keith |
dc.contributor.author | Beiske, Klaus Hermann |
dc.contributor.author | Moreno Martín-Retortillo, Lucas |
dc.date.accessioned | 2022-11-14T12:17:40Z |
dc.date.available | 2022-11-14T12:17:40Z |
dc.date.issued | 2022-11-01 |
dc.identifier.citation | Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, et al. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer. 2022 Nov 1;128(21):3775–83. |
dc.identifier.issn | 1097-0142 |
dc.identifier.uri | https://hdl.handle.net/11351/8463 |
dc.description | Criteris de consens; Fase inicial; Neuroblastoma |
dc.description.sponsorship | National Cancer Institute Pediatric and Adolescent Solid Tumor Steering Committee; Alex's Lemonade Stand Foundation for Childhood Cancer; Ben Towne Foundation; EVAN Foundation; Cancer Research UK Institute of Cancer Research, Grant/Award Number C347/A15403; National Institute for Health Research Research Methods Programme/Institute of Cancer Research Biomedical Research Centre. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Cancer;128(21) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Presa de decisions |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Neuroblastoma - Tractament |
dc.subject.mesh | Neuroblastoma |
dc.subject.mesh | /therapy |
dc.subject.mesh | Consensus |
dc.subject.mesh | Treatment Outcome |
dc.title | Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/cncr.34445 |
dc.subject.decs | neuroblastoma |
dc.subject.decs | /terapia |
dc.subject.decs | consenso |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1002/cncr.34445 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Park JR] Seattle Children’s Hospital, Seattle, Washington, USA. Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA. [Villablanca JG] Children’s Hospital Los Angeles, Los Angeles, California, USA. Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [Hero B] Children’s Hospital, University of Cologne, Cologne, Germany. [Kushner BH] Memorial Sloan Kettering Cancer Center, New York, New York, USA. [Wheatley K] University of Birmingham, Birmingham, UK. [Beiske KH] Department of Pathology, Oslo University Hospital, Oslo, Norway. [Moreno L] Servei d'Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 36101004 |
dc.identifier.wos | 000853296100001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |